ANGPT2 and neoplasm: In preclinical tests, vanucizumab inhibited angiogenesis, tumor growth, and micrometastatic seeds more effectively than mono-specific anti-Ang-2 or anti-VEGF mAbs, and led to an enhanced vessel maturation phenotype [16].